{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:59:29Z","timestamp":1742385569672,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mixed medullary and follicular cell-derived thyroid carcinoma (MMFCC) is characterized by the coexistence of follicular and C cell\u2013derived tumour cell populations within the same lesion. Due to its rarity, its etiology and clinical course remain unclear, and treatment for advanced or recurrent cases has not been established.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report a case of MMFCC treated with selpercatinib. The patient was a 69-year-old male presenting with tumors in the right thyroid lobe and in the upper mediastinum. Fine-needle aspiration (FNA) cytology of the right thyroid lobe tumor revealed a medullary carcinoma; germline <jats:italic>RET<\/jats:italic> mutations were not detected. After resection of the right thyroid lobe with central node dissection, rapid intraoperative diagnosis of the mediastinal mass confirmed malignancy, leading to total thyroidectomy with excision of the upper mediastinal tumor. Histologically, the tumor in the right thyroid lobe and the pretracheal lymph node revealed a mixture of medullary and follicular carcinoma components, diagnosed as MMFCC. The mediastinal lymph node exhibited only medullary carcinoma components. At 11\u00a0months postoperatively, computed tomography scans showed enlargement of the right supraclavicular and upper mediastinal lymph nodes. FNA cytology of the right supraclavicular lymph node suggested the recurrence of medullary thyroid carcinoma. The gene panel testing (The Oncomine Dx Target Test Multi-CDx system\u00ae, Thermo Fisher SCIENTIFIC) of metastatic lymph node revealed <jats:italic>RET<\/jats:italic> somatic mutation (M918T). Treatment with selpercatinib was initiated, and both the cervical and mediastinal lymph nodes showed a reduction in size.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We report a rare case of selpercatinib use for MMFCC. Since <jats:italic>RET<\/jats:italic> mutations may occur frequently in MMFCC, selpercatinib could be effective in treating MMFCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40792-024-01898-7","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T05:01:54Z","timestamp":1713762114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Selpercatinib for treating recurrent mixed medullary and follicular cell-derived thyroid carcinoma: a case report"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2576-9946","authenticated-orcid":false,"given":"Mei","family":"Kadoya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyasu","family":"Suganuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Takase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eita","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soji","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Masudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"1898_CR1","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/dc.21560","volume":"39","author":"AN Hanna","year":"2011","unstructured":"Hanna AN, Michael CW, Jing X. Mixed medullary-follicular carcinoma of the thyroid: diagnostic dilemmas in fine-needle aspiration cytology. Diagn Cytopathol. 2011;39:862\u20135.","journal-title":"Diagn Cytopathol"},{"key":"1898_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2559.1990.tb01559.x","volume":"16","author":"LH Sobin","year":"1990","unstructured":"Sobin LH. Histological typing of thyroid tumours. Histopathology. 1990;16:513.","journal-title":"Histopathology"},{"key":"1898_CR3","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0002-9440(10)65465-X","volume":"155","author":"M Volante","year":"1999","unstructured":"Volante M, Papotti M, Roth J, Saremaslani P, Speel EJ, Lloyd RV, et al. Mixed medullary-follicular thyroid carcinoma. Molecular evidence for a dual origin of tumor components. Am J Pathol. 1999;155:1499\u2013509.","journal-title":"Am J Pathol"},{"key":"1898_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF03343809","volume":"24","author":"F Orlandi","year":"2001","unstructured":"Orlandi F, Chiefari E, Caraci P, Mussa A, Gonzatto I, De Giuli P, et al. RET proto-oncogene mutation in a mixed medullary-follicular thyroid carcinoma. J Endocrinol Invest. 2001;24:51\u20135.","journal-title":"J Endocrinol Invest"},{"key":"1898_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.4103\/2230-8210.113776","volume":"17","author":"V Gupta","year":"2013","unstructured":"Gupta V. Simultaneous presentation of giant pheochromocytoma, primary hyperparathyroidism, and mixed-medullary-papillary thyroid cancer in MEN 2A. Indian J Endocrinol Metab. 2013;17:751\u20135.","journal-title":"Indian J Endocrinol Metab"},{"key":"1898_CR6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2174\/1871530320666200713092633","volume":"21","author":"XP Qi","year":"2021","unstructured":"Qi XP, Lin GB, Chen B, Li F, Cao ZL, Zheng WH, et al. Multiple endocrine neoplasia Type 2B associated mixed medullary and follicular thyroid carcinoma in a Chinese patient with RET M918T germline mutation. Endocr Metab Immune Disord Drug Targets. 2021;21:554\u201360.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"1898_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4165","volume":"9","author":"V Guerreiro","year":"2021","unstructured":"Guerreiro V, Costa C, Oliveira J, Santos AP, Farinha M, J\u00e1come M, et al. Mixed medullary-papillary thyroid carcinoma with mixed lymph node metastases: a case report. Clin Case Rep. 2021;9: e04165.","journal-title":"Clin Case Rep"},{"key":"1898_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567\u2013610.","journal-title":"Thyroid"},{"key":"1898_CR9","unstructured":"Haddad RI, et al. NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma, Version 2.2024. www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf. Accessed 8 April 2024."},{"key":"1898_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2169\/internalmedicine.50.4749","volume":"50","author":"I Ueki","year":"2011","unstructured":"Ueki I, Ando T, Haraguchi A, Horie I, Imaizumi M, Hayashi T, et al. A case of mixed medullary and follicular cell carcinoma of the thyroid. Intern Med. 2011;50:1313\u20136.","journal-title":"Intern Med"},{"key":"1898_CR11","first-page":"CS31","volume":"14","author":"P Maruna","year":"2008","unstructured":"Maruna P, Duskova J, Limanova Z, Dvorakov\u00e1 S, Vaclavikova E, Bendlova B. Mixed medullary and follicular cell carcinoma of the thyroid in a 71-year-old man with history of malignant melanoma. Med Sci Monit. 2008;14:CS31\u20136.","journal-title":"Med Sci Monit"},{"key":"1898_CR12","first-page":"109","volume":"17","author":"M Papotti","year":"2000","unstructured":"Papotti M, Volante M, Komminoth P, Sobrinho-Sim\u00f5es M, Bussolati G. Thyroid carcinomas with mixed follicular and C-cell differentiation patterns. Semin Diagn Pathol. 2000;17:109\u201319.","journal-title":"Semin Diagn Pathol"},{"key":"1898_CR13","first-page":"300","volume":"61","author":"I Kostoglou-Athanassiou","year":"2004","unstructured":"Kostoglou-Athanassiou I, Athanassiou P, Vecchini G, Gogou L, Kaldrymides P. Mixed medullary-follicular thyroid carcinoma. Report of a case and review of the literature. Horm Res. 2004;61:300\u20134.","journal-title":"Horm Res"},{"key":"1898_CR14","doi-asserted-by":"publisher","first-page":"16337","DOI":"10.1007\/s00432-023-05326-5","volume":"149","author":"Y Li","year":"2023","unstructured":"Li Y, Guo T, Gao X, Liu J. The novel prognostic nomograms for predicting cancer-specific survival and overall survival in mixed medullary and follicular cell carcinoma: a SEER-based study. J Cancer Res Clin Oncol. 2023;149:16337\u201354.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1898_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383:825\u201335.","journal-title":"N Engl J Med"},{"key":"1898_CR16","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","volume":"389","author":"J Hadoux","year":"2023","unstructured":"Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med. 2023;389:1851\u201361.","journal-title":"N Engl J Med"},{"key":"1898_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson GC, Kerbel R, Ellis LM, Harris AH. Antiangiogenic therapy in oncology\u202f: current status and future directions. Lancet. 2016;388:518\u201329.","journal-title":"Lancet"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-024-01898-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40792-024-01898-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-024-01898-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T05:05:57Z","timestamp":1713762357000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-024-01898-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1186\/s40792-024-01898-7","relation":{},"ISSN":["2198-7793"],"issn-type":[{"type":"electronic","value":"2198-7793"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and the accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publications was obtained from the participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}